Novartis Phase II MBG453 in combination with Venetoclax and Azacitidine in AML

Clinical Trial Grant

Duke Scholars

Principal Investigator Harry Paul Erba Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

June 2, 2020

End Date

April 30, 2028

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

June 2, 2020

End Date

April 30, 2028